Stephen Basil Thomas - Aug 7, 2025 Form 4 Insider Report for Climb Bio, Inc. (CLYM)

Role
Director
Signature
/s/ Chandra Adams, as Attorney-in-Fact
Stock symbol
CLYM
Transactions as of
Aug 7, 2025
Transactions value $
$0
Form type
4
Date filed
8/11/2025, 04:15 PM
Previous filing
Jul 1, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Thomas Stephen Basil Director C/O CLIMB BIO, INC., 20 WILLIAM STREET, SUITE 145, WELLESLEY HILLS /s/ Chandra Adams, as Attorney-in-Fact 2025-08-11 0002027962

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLYM Common Stock Award $0 +100K +49.14% $0.00 305K Aug 7, 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 27, 2024, the reporting person was granted restricted stock units ("RSUs") to acquire a total of 100,375 shares of common stock that vested based on the achievement of certain performance-based milestones and subject to continuous service. On August 7, 2025, the milestones were deemed to be achieved, resulting in the vesting of the RSUs as to all 100,375 shares.